- Home
- BAH vs NBIX Comparison
BAH vs NBIX Comparison
Compare BAH & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAH | NBIX |
|---|---|---|
| Founded | 1914 | 1992 |
| Country | United States | United States |
| Employees | 32500 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 14.4B |
| IPO Year | 2010 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BAH | NBIX |
|---|---|---|
| Price | $88.48 | $155.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $111.33 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 1.9M | 969.9K |
| Earning Date | 10-24-2025 | 10-28-2025 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | 3.12 | ★ 12.44 |
| EPS | ★ 6.54 | 4.19 |
| Revenue | ★ $11,706,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | $2.57 | $18.01 |
| P/E Ratio | ★ $13.46 | $37.10 |
| Revenue Growth | 2.42 | ★ 19.61 |
| 52 Week Low | $79.23 | $84.23 |
| 52 Week High | $149.27 | $157.67 |
Technical Indicators
Market Signals| Indicator | BAH | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 64.81 |
| Support Level | $80.81 | $150.26 |
| Resistance Level | $89.11 | $154.35 |
| Average True Range (ATR) | 2.10 | 4.16 |
| MACD | 1.15 | 1.07 |
| Stochastic Oscillator | 88.41 | 93.25 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.